Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482248 | 0.94 | ELANE (0.73) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8345071 | 0.91 | ELANE (1.00) | ELANECYP2C9CYP3A4 | |
| SCHEMBL1764173 | 0.91 | ELANE (1.00) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3481894 | 0.90 | ELANE (0.72) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3482188 | 0.88 | ELANE (0.65) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3482523 | 0.87 | ELANE (0.68) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13412207 | 0.86 | ELANE (0.89) | ELANECYP2C9CYP3A4 | |
| SCHEMBL3482010 | 0.85 | ELANE (0.69) | ELANECYP2C9CYP3A4 | |
| SCHEMBL8344908 | 0.85 | ELANE (0.87) | ELANECYP2C9CYP3A4 | |
| SCHEMBL13872930 | 0.85 | ELANE (0.87) | ELANECYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010024-A1 | USE OF1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010024-A1 | USE OF1,4-DIARYL-DIHYDROPYRIMIDINE-2-ON DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTENSION | PTGS1, DPYD, PTGIS | ELANE 2990/4885CYP2C9 1968/4885CYP3A4 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.